Incyte stock forecast 2027–2029
MyStockButler's October 2026 analysis: Incyte’s weighted forecast puts the share price at $90.98 in October 2027. Incyte’s outlook hinges on whether replacement products offset JAKAFI’s patent-driven decline.
Where could Incyte’s shares be by 2029?
The weighted forecast puts the share price at $90.98 in October 2027. That implies a −20% return. It puts the price at $61.36 in October 2029. That implies a −46% return, hinging on whether replacement products offset JAKAFI’s patent-driven decline.
The bear case carries 30% probability. The base case carries 50%. The bull case carries 20%. The case turns on JAKAFI demand, XR conversion and generic-entry timing. XR is an extended-release form designed to release its dose over a longer period. Latarcibart headline results are expected in early 2029.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 30 % | 56.39 (-50 %) | 34.88 (-69 %) | 23.10 (-80 %) |
| Base | 50 % | 94.15 (-17 %) | 71.64 (-37 %) | 50.95 (-55 %) |
| Bull | 20 % | 134.93 (+19 %) | 148.06 (+31 %) | 144.76 (+28 %) |
| Weighted | 100 % | 90.98 (-20 %) | 75.90 (-33 %) | 61.36 (-46 %) |
What has to go right or wrong for Incyte?
The bear case gives revenue of $5,800M, then $5,700M and $5,400M. Margins fall from 20% to 16% and then 13%, producing earnings of $1,160M, $912M and $702M. The bull case gives revenue of $6,300M, $6,800M and $7,300M, with margins of 24%, 23% and 22%. Earnings reach $1,512M, $1,564M and $1,606M. The bull requires stronger adoption, effective access, meaningful Jakafi XR conversion and positive pipeline progress. Jakafi generated $3,092.515M in 2025, and management expects sales to decline after patent exclusivity ends in 2028.
How much cash does Incyte really make?
Stock compensation is a separate economic cost. Incyte paid employees partly in shares, preserving cash today but giving employees a claim on future earnings. Subtracting that noncash expense produces a more shareholder-focused measure of free cash flow. In 2024, reported free cash flow was positive but this adjusted remainder was negative.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 1,413,498 | 335,337 | 496,487 | 969,941 | 749,488 |
| Of which, freed from working capital | 138,244 | 198,810 | |||
| Of which, tied up in working capital | 527,162 | 248,651 | 14,569 | ||
| − Capital spending | 58,867 | 86,263 | 32,486 | 77,833 | 181,006 |
| = Free cash flow | 1,354,631 | 249,074 | 464,001 | 892,108 | 568,482 |
| − Stock pay | 249,346 | 266,058 | 215,889 | 188,420 | 183,006 |
| = Real free cash flow | 1,105,285 | -16,984 | 248,112 | 703,688 | 385,476 |
What this means. Stock pay is not cash paid out today, but we subtract it because giving employees shares reduces the part of the company left for shareholders.
What does an investor pay for Incyte today?
At $113.44 a share, Incyte’s trailing P/E is 14.5x. The P/E compares the share price with earnings per share, so it shows what investors pay for each dollar the company earned over the past twelve months. Enterprise value measures the operating business after removing cash and adding debt: cash lowers the price because a buyer receives it, while debt raises it because a buyer effectively assumes it.
| Today (Oct 21, 2026) | |
|---|---|
| Share price | 113.44 |
| Market value (calculated) | 22,994,032.306 |
| Enterprise value (calculated) | 18,490,971.306 |
| P/E, last 12 months (calculated) | 14.5x |
| P/E, next 12 months (calculated) | 14.0x |
| Free cash flow yield (calculated) | 5.9% |
What this means. The share price is in US dollars per share, while the market value and enterprise value are shown in thousands of US dollars, so their numbers should not be compared directly.